Guidelines, pharmacoeconomic assessments, and policies for reimbursement can make comparisons in pharmacoepidemiological studies difficult to conduct due to selection bias and confounding.

Use of a contextual cohort could be considered as an option to characterise the adoption of new medications into clinical practice and describe the prevalence of clinical characteristics and risk factors.